Fig. 4 | Nature Communications

Fig. 4

From: CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

Fig. 4

Safety of the expression of CRISPR/Cas9 system. a Representative hematoxylin-eosin staining and CD45+ IHC of liver sections from 8–10-week-old PH1 animals sacrificed 4 months after treatment with saline (n = 7), Cas9 (n = 6), Hao1-g1 (n = 6) and Hao1-g2 (n = 5). Scale bar: 200 μm. b Quantification of CD45+ areas (%) of liver sections. (c, d) Serum ALT (U/L) (c) and bilirubin (mg/dL) (d) levels measured in animals sacrificed 6 months after treatment. Mean ± SEM of data are presented. Kruskal–Wallis test revealed no significant differences between groups. Dotted lines represent the range of normal reference values for ALT and bilirubin serum levels

Back to article page